カタログ >
Randox Laboratories/ランドックス >
LT253-Molecular-Diagnostics-Print-Version-Contrast

LT253-Molecular-Diagnostics-Print-Version-Contrast
1 / 20ページ

お気に入りに追加する　

カタログの抜粋

LT253-Molecular-Diagnostics-Print-Version-Contrast - 1

MOLECULAR DIAGNOSTICS Precise diagnostics for targeted therapy

カタログの1ページ目を開く

LT253-Molecular-Diagnostics-Print-Version-Contrast - 2

BIOCHIP ARRAY TECHNOLOGY Removable strip of three wells Single reaction well 25 discrete test regions

カタログの2ページ目を開く

LT253-Molecular-Diagnostics-Print-Version-Contrast - 3

1 BIOCHIP PROVIDING 22 RESULTS THROUGH RAPID AND ACCURATE TESTING

カタログの3ページ目を開く

LT253-Molecular-Diagnostics-Print-Version-Contrast - 4

RESPIRATORY TESTING KRAS TESTING Randox Biosciences is dedicated to advancing scientific discovery, drug development and diagnostics. Spanning four key divisions; Life Sciences, Pharma Sciences, Research and Molecular; Randox Biosciences offers complete tailored solutions for clinical and research use. From initial cultivation of raw materials for assay development, through to providing companion diagnostics, molecular and custom based assays across a range of therapy areas, Randox Biosciences is a trusted partner supplying quality diagnostic solutions to the clinical, life science,...

カタログの4ページ目を開く

LT253-Molecular-Diagnostics-Print-Version-Contrast - 5

MOLECULAR DIAGNOSTIC ARRAYS PATHOGEN DETECTION MUTATION DETECTION STI and Respiratory Multiplex Arrays KRAS BRAF PIK3CA Array and Familial Hypercholesterolemia (FH) Arrays I & II Cardiovascular Risk Prediction Array Both arrays detect the most common and frequently requested infections in sexual and respiratory health. These unique biochip assays permit high discrimination between multiple targets in a number of genes with a rapid turnaround time (3 hours). The arrays enable detection of the most frequently occurring mutations known to cause disease (FH) and adversely affect patient...

カタログの5ページ目を開く

LT253-Molecular-Diagnostics-Print-Version-Contrast - 6

MOLECULAR TESTING WITH EVIDENCE INVESTIGATOR Rapid, Accurate & Comprehensive Molecular Testing The Randox molecular arrays are analysed on the Evidence Investigator analyser. This analyser offers complete patient profiling with the most comprehensive test menu on the market. The Evidence Investigator is a compact, semiautomated bench top platform, consolidating immunoassay and molecular diagnostics on a single platform with protein and DNA biochips. The technology allows simultaneous detection of multiple analytes from a single sample for efficient and cost-effective testing. Each single...

カタログの6ページ目を開く

LT253-Molecular-Diagnostics-Print-Version-Contrast - 7

MOLECULAR BIOCHIP TESTING PROCESS EXTRACT DNA/RNA Extract nucleic acid MULTIPLEX PCR Single tube amplification using Randox multi-target primer sets HYBRIDISATION Biotin-labelled amplified PCR product binds to corresponding unique biochip molecular probe WASH STEP Rinse away any unbound product CONJUGATION Addition of streptavidin labelled-horse radish peroxidase to produce a biotinstreptavidin-enzyme complex WASH STEP Rinse away any unbound conjugate SIGNAL REAGENT Addition of equal volumes of luminol and peroxide to produce chemiluminescent biochip spot signal SIGNAL DETECTION RESULT...

カタログの7ページ目を開く

LT253-Molecular-Diagnostics-Print-Version-Contrast - 8

Comprehensive, simultaneous detection of 10 common sexually transmitted infections STIs and related complications, such as infertility or reproductive health problems, represent a significant public health issue in both developed and developing countries. Many infections are asymptomatic and can remain undiagnosed, increasing the risk of unhindered spread in the sexually active population. If untreated, STIs can impact fertility, increase risk of ectopic pregnancies and infant mortality. According to the World Health Organisation (WHO), more than 1 million people acquire a sexually...

カタログの8ページ目を開く

LT253-Molecular-Diagnostics-Print-Version-Contrast - 9

Neisseria gonorrhoea (NG) Mycoplasma genitalium (MG) Ureaplasma urealyticum (UU) Chlamydia trachomatis (CT) Trichomonas vaginalis (TV) Haemophilus ducreyi (HD) Mycoplasma hominis (MH) Treponema pallidum (TP) Herpes simplex Virus 1 (HSV-1) Herpes simplex Virus 2 (HSV-2) Nucleic acid is extracted from urine or urogenital swab samples Single tube 10-plex PCR reaction PATIENT • Detection of primary, secondary and asymptomatic co-infections ensures the patient is diagnosed accurately first-time • Reduces length of exposure to infection, which can impact fertility and reproductive health •...

カタログの9ページ目を開く

LT253-Molecular-Diagnostics-Print-Version-Contrast - 10

Simultaneous detection of 22 bacterial and viral pathogens within the upper and lower respiratory tracts RESPIRATORY MULTIPLEX ARRAY RESPIRATORY TESTING Respiratory tract infections are caused by many viral and bacterial pathogens and are the second most common cause of morbidity and mortality worldwide.1 Acute respiratory diseases (ARD) accounts for more than 4 million deaths annually and are the leading cause of death in developing countries.2 Viral respiratory infections can occur in epidemics and can spread rapidly within communities across the globe. Every year, influenza causes...

カタログの10ページ目を開く

LT253-Molecular-Diagnostics-Print-Version-Contrast - 11

RESPIRATORY TESTING 22 VIRAL & BACTERIAL PATHOGENS Influenza A Influenza B Human adenovirus A/B/C/D/E Human bocavirus 1/2/3 Human coronavirus 229E/NL63 Human coronavirus OC43/HKU1 Human enterovirus A/B/C Human Metapneumovirus Human parainfluenza virus 1 Bordetella pertussis Human parainfluenza virus 2 Chlamydophila pneumoniae Human parainfluenza virus 3 Haemophilus influenzae Human parainfluenza virus 4 Legionella pneumophila Human respiratory syncytial virus A Moraxella catarrhalis Human respiratory syncytial virus B Mycoplasma pneumoniae Streptococcus pneumoniae RNA and DNA is extracted...

カタログの11ページ目を開く

LT253-Molecular-Diagnostics-Print-Version-Contrast - 12

KRAS TESTING KRAS BRAF cell signalling pathway • apid turnaround time of ~3 hours R from extracted genomic DNA to result Colorectal cancer (CRC) is the third most common cancer worldwide.1 Despite recent therapeutic advances, the prognosis for patients with metastatic CRC (mCRC) remains poor.3 In recent years monoclonal antibodies (moAbs), like cetuximab and panitumumab, have proven to be effective in the treatment of mCRC.4,5 These moAbs block the signal from EGFR inhibiting downstream signalling including KRAS, BRAF and PIK3CA mediated events. However, when KRAS, BRAF and PIK3CA are...

カタログの12ページ目を開く

LT253-Molecular-Diagnostics-Print-Version-Contrast - 13

KRAS TESTING Genomic DNA is extracted from fresh/ frozen or FFPE tissue samples Single tube 20-plex PCR reaction PATIENT • Early diagnosis and detection of mutational status informs selection of appropriate treatment regime in cases of colorectal cancer, for which current treatment options are limited. Therefore, identification of the correct treatment pathway for individual patients based on their mutational status is of paramount importance for optimal patient outcomes LABORATORY • R apid simultaneous detection of 20 key mutations • An efficient and cost-effective method for determining...

カタログの13ページ目を開く